Valtrex Dosing Recommendations
For adult patients, valacyclovir dosing varies significantly by indication: use 2 grams every 12 hours for 1 day for cold sores, 1 gram twice daily for 10 days for initial genital herpes, 500 mg twice daily for 3 days for recurrent genital herpes, 1 gram once daily for suppressive therapy, and 1 gram three times daily for 7 days for herpes zoster. 1
Adult Dosing by Indication
Cold Sores (Herpes Labialis)
- 2 grams every 12 hours for 1 day (single-day therapy) 1
- This high-dose, short-duration regimen is highly convenient and effective for orolabial lesions
Genital Herpes - Initial Episode
- 1 gram twice daily for 10 days 1
- May extend treatment if healing incomplete after 10 days 2
- This dose is equivalent in efficacy to acyclovir 200 mg five times daily but offers superior convenience 3
Genital Herpes - Recurrent Episodes
- 500 mg twice daily for 3 days 1
- Start at first sign of prodrome or lesion onset for maximum benefit 2
- The 3-day regimen is equivalent to 5-day treatment for recurrent episodes 4
- Alternative from older guidelines: 500 mg twice daily for 5 days 2
Genital Herpes - Suppressive Therapy
For immunocompetent patients:
- 1 gram once daily (standard dose) 1
- Alternative: 500 mg once daily for patients with ≤9 recurrences per year 1
- Important caveat: The 500 mg once-daily dose is less effective in patients with ≥10 recurrences per year; use 1 gram once daily or 500 mg twice daily in these patients 2
For HIV-infected patients:
- 500 mg twice daily 1, 5
- Higher doses needed due to more frequent and severe recurrences in immunocompromised patients 5
Genital Herpes - Reduction of Transmission
- 500 mg once daily 1
- For use in serodiscordant couples to reduce transmission risk
Herpes Zoster (Shingles)
- 1 gram three times daily for 7 days 1
- Start within 72 hours of rash onset for optimal efficacy
Pediatric Dosing
Cold Sores (≥12 years)
- 2 grams every 12 hours for 1 day 1
- Same as adult dosing
Chickenpox (Ages 2 to <18 years)
- 20 mg/kg three times daily for 5 days 1
- Maximum dose: 1 gram three times daily 1
- Oral suspension (25 mg/mL or 50 mg/mL) can be compounded from 500 mg tablets 1
Mucocutaneous HSV in Children
- For children <45 kg: 20 mg/kg (max 400 mg/dose) three times daily for 5-14 days 6
- For adolescents: 400 mg twice daily for 5-14 days 6
- Note: Valacyclovir is approved for adults but used off-label in younger children; acyclovir remains the preferred agent in many pediatric scenarios 6
Special Populations and Considerations
HIV-Infected Patients
- Use 500 mg twice daily for suppressive therapy rather than once-daily dosing 5, 1
- May require longer treatment courses for acute episodes (5-14 days vs. 3-5 days) 5
- Avoid valacyclovir doses of 8 grams/day due to risk of thrombotic thrombocytopenic purpura/hemolytic uremic syndrome 5, 2, 1
Severe Disease Requiring Hospitalization
- Switch to IV acyclovir 5-10 mg/kg every 8 hours for disseminated infection, pneumonitis, hepatitis, or CNS complications (meningitis/encephalitis) 2
- Valacyclovir is not appropriate for severe, life-threatening HSV infections
Renal Impairment
- Dose reduction required based on creatinine clearance 1
- Elderly patients are at higher risk for acute renal failure and CNS adverse reactions; use caution and adjust doses appropriately 1
Key Clinical Pitfalls
Avoid these common errors:
- Do not use 500 mg once-daily suppressive therapy in patients with ≥10 recurrences/year—this dose is inadequate 2
- Do not use valacyclovir for severe HSV disease requiring hospitalization; IV acyclovir is mandatory 2
- Do not use high doses (8 grams/day) in immunocompromised patients due to TTP/HUS risk 5, 2, 1
- Do not forget renal dose adjustments in elderly patients or those with renal impairment 1
Comparative Efficacy Notes
Valacyclovir offers equivalent efficacy to acyclovir with superior convenience due to less frequent dosing 2, 3. The improved bioavailability (3-5 times higher than acyclovir) allows for twice-daily or once-daily dosing versus five-times-daily acyclovir 3. This enhanced convenience likely improves adherence, particularly for chronic suppressive therapy 2.